Abstract
The Ras-MAPK pathway is important to orchestrating a cells response to external and internal stimuli. This pathway is commonly dysregulated in cancer, including bladder cancer. Multiple components of this complex pathway have been identified as potential targets for drug development. After initial preclinical studies many drugs targeting the Ras-MAPK pathway are being studied in phase II clinical trials for advanced bladder cancer either alone or in combination with other chemotherapeutic agents. Drugs presently in clinical trials inhibit the tyrosine kinases, including FGFR, EGFR, ERBB2, and PDGF, either through small molecule tyrosine kinase, dual kinase or farnesyltransferase inhibitors. Recent drug patents targeting the Ras-MAPK pathway in cancer are becoming more selective with the potential for improved therapeutic response and better toxicity as compared to the more universal MAPK pathway inhibitors. In the present review we summarize the importance of the Ras-MAPK pathway in cancer with a focus on bladder cancer and discuss current drugs and recent patents (2004-2008) that target this important pathway in bladder cancer.
Keywords: Bladder cancer, Ras-MAPK pathway, new potential therapeutic targets
Recent Patents on Anti-Cancer Drug Discovery
Title: Ras-MAPK Pathway as a Therapeutic Target in Cancer - Emphasis on Bladder Cancer
Volume: 4 Issue: 2
Author(s): Pankaj P. Dangle, Boriana Zaharieva, Hongtao Jia and Kamal S. Pohar
Affiliation:
Keywords: Bladder cancer, Ras-MAPK pathway, new potential therapeutic targets
Abstract: The Ras-MAPK pathway is important to orchestrating a cells response to external and internal stimuli. This pathway is commonly dysregulated in cancer, including bladder cancer. Multiple components of this complex pathway have been identified as potential targets for drug development. After initial preclinical studies many drugs targeting the Ras-MAPK pathway are being studied in phase II clinical trials for advanced bladder cancer either alone or in combination with other chemotherapeutic agents. Drugs presently in clinical trials inhibit the tyrosine kinases, including FGFR, EGFR, ERBB2, and PDGF, either through small molecule tyrosine kinase, dual kinase or farnesyltransferase inhibitors. Recent drug patents targeting the Ras-MAPK pathway in cancer are becoming more selective with the potential for improved therapeutic response and better toxicity as compared to the more universal MAPK pathway inhibitors. In the present review we summarize the importance of the Ras-MAPK pathway in cancer with a focus on bladder cancer and discuss current drugs and recent patents (2004-2008) that target this important pathway in bladder cancer.
Export Options
About this article
Cite this article as:
Dangle P. Pankaj, Zaharieva Boriana, Jia Hongtao and Pohar S. Kamal, Ras-MAPK Pathway as a Therapeutic Target in Cancer - Emphasis on Bladder Cancer, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (2) . https://dx.doi.org/10.2174/157489209788452812
DOI https://dx.doi.org/10.2174/157489209788452812 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches
Current Signal Transduction Therapy Tocilizumab Labeling with 99mTechnetium via HYNIC as a Molecular Diagnostic Agent for Multiple Myeloma
Anti-Cancer Agents in Medicinal Chemistry Natural and Synthetic Agents Targeting Inflammation and Angiogenesis for Chemoprevention of Prostate Cancer
Current Cancer Drug Targets TRICOM Vector Based Cancer Vaccines
Current Pharmaceutical Design Isothiocyanates in the Chemoprevention of Bladder Cancer
Current Drug Metabolism The Pathogenic Role of Intestinal Flora in IBD and Colon Cancer
Current Drug Targets Hypersensitivity to Aurora Kinase Inhibitors in Cells Resistant against Platinum- Containing Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Transition Metal Based Anticancer Drugs
Current Topics in Medicinal Chemistry Network Effect of Wt-mutant p53 Interactions and Implications on p53 Gene Therapy
Current Pharmaceutical Design Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry Cell Death in Mammalian Development
Current Pharmaceutical Design Hypertension in the Elderly: An Evidence-based Review
Current Pharmaceutical Design Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets Involvement of Leukotriene Pathway in the Pathogenesis of Ischemia- Reperfusion Injury and Septic and Non-Septic Shock
Current Vascular Pharmacology Immunotherapy in Bladder Cancer
Current Molecular Pharmacology Radioprotective Gene Therapy
Current Gene Therapy HER-2 Signaling and Inhibition in Breast Cancer
Current Cancer Drug Targets Observations of the Mechanisms of Electromediated DNA Uptake - From Vesicles to Tissues
Current Gene Therapy Drug Design Studies of the Novel Antitumor Targets Carbonic Anhydrase IX and XII
Current Medicinal Chemistry Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Current Cancer Drug Targets